Related Experiment Videos
[Clinical results of a rokitamycin dry syrup in pediatric infections]
1Department of Pediatrics, School of Medicine, Hirosaki University.
Abstract:
Clinical efficacies of a new macrolide antibiotic, rokitamycin (RKM, TMS-19-Q), were studied in acute pediatric infections. Responses to the RKM administration were evaluable in 62 out of 68 patients consisted of 7 patients with pharyngitis (efficacy rate of 85.7%, 6/7 patients), 4 with bronchitis (25.0%, 1/4), 9 with tonsillitis (100%, 9/9), 13 with mycoplasmal pneumonia (100%, 13/13), 13 with hemolytic streptococcal infections (92.3%, 12/13), 14 with pneumonia (57.1%, 8/14), one with pertussis (100%, 1/1) and another with Chlamydia pneumonia (100%, 1/1) thus an overall efficacy rate of 82.3% was achieved. Urticaria was observed in one of the patients as an adverse reaction to the drug, while abnormal laboratory test results were noted in 3 patients, but none of such changes were severe. The drug, even when administered in combination with a theophylline preparation, exerted no effects on the serum concentration of the latter.
Insights
Rokitamycin (RKM) demonstrated significant clinical efficacy in treating various acute pediatric infections, achieving an 82.3% overall success rate. This new macrolide antibiotic showed a favorable safety profile with minimal adverse effects in children.
Area of Science:
- Pharmacology
- Infectious Diseases
- Pediatrics
Context:
- Acute pediatric infections pose a significant health burden.
- Novel antibiotics are crucial for combating resistant pathogens.
- Macrolide antibiotics are widely used in pediatric care.
Purpose:
- To evaluate the clinical efficacy and safety of rokitamycin (RKM) in treating acute pediatric infections.
- To assess RKM's effectiveness across different bacterial and atypical infections.
- To determine RKM's potential drug interactions with theophylline.
Summary:
- Rokitamycin (RKM) was administered to 68 pediatric patients with acute infections, with 62 evaluable cases.
- High efficacy rates were observed in tonsillitis (100%), mycoplasmal pneumonia (100%), hemolytic streptococcal infections (92.3%), and Chlamydia pneumonia (100%).
- An overall efficacy rate of 82.3% was achieved, with mild adverse events (urticaria) in one patient and no significant drug interactions with theophylline.
Impact:
- Rokitamycin (RKM) shows promise as an effective treatment option for a range of acute pediatric infections.
- The favorable safety profile suggests RKM is well-tolerated in pediatric populations.
- Further research may establish RKM as a valuable addition to the pediatric antibiotic armamentarium.